Recruiting
Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Sponsor:

Mayo Clinic

Code:

NCT06639074

Conditions

Advanced Fallopian Tube Carcinoma

Advanced Fallopian Tube High Grade Serous Adenocarcinoma

Advanced Ovarian Carcinoma

Advanced Ovarian Carcinosarcoma

Advanced Ovarian Clear Cell Adenocarcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Computed Tomography

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

Leukapheresis

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information